Why Butterfly Network stock is in focus after the TD Cowen event

Butterfly Network (BFLY) is drawing attention as investors look ahead to management’s appearance at the TD Cowen Medical Devices Emerging Growth Call Series, where executives are expected to outline product priorities and commercialization efforts.

The discussion is set to cover handheld ultrasound scaling, AI powered software subscriptions, and enterprise rollouts, giving current and potential shareholders fresh context on how Butterfly Network is positioning its ultrasound ecosystem in a competitive medical devices market.

Butterfly Network’s recent trading reflects building momentum, with a 30 day share price return of 47% and year to date share price return of 50.13%, alongside a 1 year total shareholder return of 143.72% that contrasts with a 5 year total shareholder return decline of 61.83%.

If this TD Cowen event has you looking beyond one stock, it could be a useful time to see what else is happening across 39 healthcare AI stocks.

With Butterfly Network stock now trading close to the average analyst price target and recent returns already very strong, the key question is whether there is still a buying opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 1% Undervalued

At a last close of $5.63 versus a fair value of $5.69, the most followed Butterfly Network narrative treats the stock as almost fully priced with only a small margin.

Ongoing advances in semiconductor manufacturing, new product launches (e.g., iQ Station, upcoming fourth-generation P5 technology), and cost containment efforts are driving product miniaturization and lower production costs, supporting higher gross margins and a credible path to sustainable profitability at scale as portable imaging adoption accelerates globally.

Curious what sits behind that almost step change in Butterfly Network’s margin outlook? The narrative leans heavily on projected revenue compounding, a sharp swing in profitability, and a premium earnings multiple that assumes those targets are met. The precise mix of growth, margins, and valuation is where the story really gets interesting.

Result: Fair Value of $5.69 (UNDERVALUED)

However, Butterfly Network’s story can quickly change if enterprise deals take longer to close or if high R&D spending keeps profitability further out of reach.

Another View on Butterfly Network stock

The earlier narrative frames Butterfly Network as roughly in line with a $5.69 fair value based on long range earnings assumptions. A simple P/S lens tells a different story, with the stock trading at 14.3x sales versus 2.7x for the US Medical Equipment industry, 4.4x for peers, and a fair ratio of 3.4x, which points to meaningful valuation risk if sentiment cools.

For investors comparing these signals, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed sentiment around Butterfly Network stock has you undecided, use the available data to form your own view quickly and weigh up the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond Butterfly Network stock?

If you are still unsure about Butterfly Network, do not sit on your hands. Put the same scrutiny to work on a broader set of opportunities.

• Spot potential turnaround stories early by scanning 23 elite penny stocks with strong financials, which already show stronger balance sheets and fundamentals than many expect from lower priced stocks.
• Hunt for quality at a discount by reviewing the 47 high quality undervalued stocks, which combine healthier cash flows with valuations that may not fully reflect their fundamentals.
• Prioritize resilience by focusing on the 68 resilient stocks with low risk scores, which score well on financial strength and business stability before headlines start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.